Canada Pension Plan Investment Board Sells 79,684 Shares of Hologic, Inc. (NASDAQ:HOLX)

Canada Pension Plan Investment Board decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 98.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 864 shares of the medical equipment provider's stock after selling 79,684 shares during the period. Canada Pension Plan Investment Board's holdings in Hologic were worth $62,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Benson Investment Management Company Inc. bought a new stake in shares of Hologic in the fourth quarter valued at about $4,832,000. Principal Financial Group Inc. boosted its holdings in shares of Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after acquiring an additional 1,606 shares during the period. Clean Yield Group grew its position in shares of Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock valued at $3,291,000 after purchasing an additional 7,266 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock worth $110,700,000 after purchasing an additional 238,222 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after purchasing an additional 544,889 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Price Performance

Shares of NASDAQ HOLX traded down $4.58 during trading hours on Friday, reaching $52.70. 3,050,703 shares of the stock traded hands, compared to its average volume of 1,986,951. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $52.14 and a 52-week high of $84.67. The company's 50-day simple moving average is $60.50 and its two-hundred day simple moving average is $69.45. The company has a market capitalization of $11.82 billion, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the company earned $1.03 earnings per share. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on HOLX shares. Stephens reissued an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Raymond James reissued an "outperform" rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. William Blair restated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Finally, Citigroup cut their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $83.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.